Professor Breedveld’s special clinical interest is in the pathophysiology of rheumatoid arthritis (RA) and the development of rational treatments for RA. The main focus of his clinical practice is connective tissue diseases, osteoarthritis (OA) and other rheumatic diseases. The focus of Professor Breedveld’s research encompasses the diagnostic aspects and predictions of disease outcomes in patients with RA, genetics of early occurring forms of OA and biochemical and genetic markers of OA.
Further information is available at: www.lumc.nl/research.html

van Esch WJ, Reparon-Schuijt CC, Hamstra HJ, van Kooten C, Logtenberg T, Breedveld FC, Verweij CL. Polyreactivity of human IgG Fc-binding phage antibodies constructed from synovial fluid CD38+ B cells of patients with rheumatoid arthritis. J Autoimmun. 2002;19:241-250.

Pascual M, Matarán L, Jones G, Shing D, van der Slik AR, Giphart MJ, Schreuder GM, de Vries RR, Breedveld FC, Roovers E, Zanelli E, Martin J. HLA haplotypes and susceptibility to rheumatoid arthritis. More than class II genes. Scand J Rheumatol. 2002;31:275-278.

Berckmans RJ, Nieuwland R, Tak PP, Böing AN, Romijn FP, Kraan MC, Breedveld FC, Hack CE, Sturk A. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum. 2002;46:2857-2866.

Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-1602.

ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MA, Markusse HM, Janssen M, van den Brink HR, Dijkmans BA. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet. 1996;347:347-352.